Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $139.74, for a total value of $4,583,472.00. Following the completion of the sale, the chief executive officer now directly owns 74,131 shares in the company, valued at approximately $10,359,065.94. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Michael A. Mussallem also recently made the following trade(s):
- On Thursday, January 4th, Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.97, for a total value of $3,771,016.00.
Shares of Edwards Lifesciences Corp (EW) traded down $1.98 during midday trading on Friday, hitting $135.32. The stock had a trading volume of 1,260,740 shares, compared to its average volume of 1,309,350. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.80 and a quick ratio of 1.41. Edwards Lifesciences Corp has a one year low of $92.44 and a one year high of $143.22. The company has a market cap of $29,208.00, a P/E ratio of 46.99, a P/E/G ratio of 2.04 and a beta of 0.56.
Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a return on equity of 27.78% and a net margin of 18.11%. The company had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. During the same period in the previous year, the company posted $0.75 EPS. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. equities analysts predict that Edwards Lifesciences Corp will post 4.52 EPS for the current fiscal year.
Edwards Lifesciences declared that its Board of Directors has approved a stock buyback program on Thursday, December 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.
EW has been the topic of a number of recent research reports. JPMorgan Chase & Co. lowered Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Barclays upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. Cowen set a $135.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research note on Sunday, December 10th. Canaccord Genuity restated a “buy” rating and issued a $174.00 price target (up from $140.00) on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Finally, Evercore ISI started coverage on Edwards Lifesciences in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 price target for the company. Three investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $144.16.
Hedge funds and other institutional investors have recently modified their holdings of the company. Cerebellum GP LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $128,000. Resources Investment Advisors Inc. boosted its stake in shares of Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock worth $132,000 after acquiring an additional 465 shares during the period. Exane Derivatives boosted its stake in shares of Edwards Lifesciences by 381.3% during the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock worth $137,000 after acquiring an additional 961 shares during the period. Lake Street Advisors Group LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $201,000. Finally, Captrust Financial Advisors bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $204,000. Institutional investors own 82.89% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/23/michael-a-mussallem-sells-32800-shares-of-edwards-lifesciences-corp-ew-stock.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.